340B Drug Pricing Program

Hospitals are urged to file by the Sept. 5 deadline comment letters on the Department of Health and Human Services’ (HHS) proposed remedy for the unlawful payment cuts to certain hospitals that participate in the 340B Drug Pricing Program.
Hospitals are urged to file by the Sept. 5 deadline comment letters on the Department of Health and Human Services’ (HHS) proposed remedy for the unlawful payment cuts to certain hospitals that participate in the 340B Drug Pricing Program.
Renown Regional Medical Center prides itself on being Northern Nevada's only Level II Trauma Center with 985 licensed beds, providing care to approximately one million patients across 17 counties, encompassing 100,000 square miles between Sacramento, Calif. and Salt Lake City.
AHA urged the House Energy and Commerce Committee to consider including in its draft legislation to address drug shortages legislative proposals that would support drug manufacturers and protect the supply chain for essential medications without limiting patient access to 340B drugs. 
The AHA filed its comment letter on the Department of Health and Human Services’ proposed remedy for the unlawful payment cuts to certain hospitals that participate in the 340B Drug Pricing Program followin
The American Hospital Association today filed its comment letter on the Department of Health and Human Services’ (HHS) proposed remedy for the unlawful payment cuts to certain hospitals that participate in the 340B Drug Pricing Program.
HHS must not pursue any “budget neutrality adjustment” in the final rule. At the very least, it must pursue a far smaller one than the proposed $7.8 billion “adjustment.”
AHA is greatly disappointed that HHS chose to propose “budget neutrality adjustments” to offset this legally-required remedy. The statutes that HHS relies on in its proposed rule do not give it the authority to make a “budget neutrality adjustment.”